BioLineRx to Report First Quarter 2023 Results on May 24, 2023
Management to Hold Conference Call at
The Company will host a conference call on
To access the conference call, please dial +1-888-281-1167 from the
About
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a pre-commercial-stage biopharmaceutical company focused on oncology. The Company's lead development program, motixafortide, a novel selective inhibitor of the CXCR4 chemokine receptor, may support diverse therapeutic approaches in oncology and other diseases. Motixafortide was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous transplantation for multiple myeloma patients and has had its NDA submission accepted by the FDA with an assigned PDUFA date of September 9, 2023. Motixafortide was also successfully evaluated in a Phase 2a study for the treatment of metastatic pancreatic cancer (mPDAC) in combination with the PD-1 inhibitor pembrolizumab and chemotherapy and is currently being studied in combination with the PD-1 inhibitor cemiplimab and chemotherapy as a first line mPDAC therapy. In addition, a randomized phase 2b study with 200 patients assessing motixafortide in combination with a PD-1 inhibitor and chemotherapy as a first line mPDAC therapy is expected to initiate in 2023.
CONTACTS
IR@biolinerx.com
moran@lifesciadvisors.com
View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-first-quarter-2023-results-on-may-24-2023-301826333.html
SOURCE